Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Discover the difference between burnout vs depression, including causes, symptoms, and how both are treated, according to ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...